3,4-Methylenedioxy-N-hydroxyamphetamine: Difference between revisions
Appearance
Content deleted Content added
mNo edit summary |
m task, replaced: : → : |
||
(48 intermediate revisions by 33 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Psychedelic amphetamine}} |
|||
{{Drugbox |
|||
{{DISPLAYTITLE:3,4-Methylenedioxy-''N''-hydroxyamphetamine}} |
|||
⚫ | |||
{{Infobox drug |
|||
| image = Methylenedioxyhydroxyamphetamine.png |
|||
| drug_name = 3,4-Methylenedioxy-''N''-hydroxyamphetamine |
|||
⚫ | |||
⚫ | |||
⚫ | |||
| image = MDOH_structure.svg |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| chemical_formula = C<sub>10</sub>H<sub>13</sub>NO<sub>3</sub> |
|||
| molecular_weight = 195.22 g/mol |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| legal_status = |
|||
⚫ | |||
⚫ | |||
<!--Clinical data--> |
|||
⚫ | '''3,4-Methylenedioxy-''N''-hydroxyamphetamine''' ('''MDOH''', '''MDH''') is an [[entactogen]], [[ |
||
| tradename = |
|||
⚫ | |||
| legal_CA = Schedule I |
|||
| legal_UK = Class A |
|||
| legal_DE = Anlage I |
|||
| legal_US = Schedule I |
|||
| legal_UN = P I |
|||
⚫ | |||
<!--Pharmacokinetic data--> |
|||
== See also == |
|||
⚫ | |||
* [[Substituted Methylenedioxyphenethylamine]] |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
<!--Identifiers--> |
|||
⚫ | |||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| UNII = SJE1T2B1A7 |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| KEGG = C22807 |
|||
⚫ | |||
<!--Chemical data--> |
|||
| C=10 | H=13 | N=1 | O=3 |
|||
⚫ | |||
⚫ | |||
⚫ | '''3,4-Methylenedioxy-''N''-hydroxyamphetamine''' ('''MDOH''', '''MDH''', '''N-hydroxytenamphetamine''') is an [[entactogen]], [[psychedelic drug|psychedelic]], and [[stimulant]] of the [[substituted phenethylamine|phenethylamine]] and [[substituted amphetamine|amphetamine]] [[chemical class]]es.<ref name="de_Boer_2004">{{cite journal | vauthors = de Boer D, Bosman I | title = A new trend in drugs-of-abuse; the 2C-series of phenethylamine designer drugs | journal = Pharmacy World & Science | volume = 26 | issue = 2 | pages = 110–113 | date = April 2004 | pmid = 15085947 | doi = 10.1023/b:phar.0000018600.03664.36 }}</ref> It is the ''N''-[[hydroxyl|hydroxy]] [[Homologous series|homologue]] of [[3,4-Methylenedioxyamphetamine|MDA]], and the ''N''-[[desmethyl]] homologue of [[methylenedioxyhydroxymethamphetamine|MDHMA]]. MDOH was first [[Organic synthesis|synthesized]] and [[assay]]ed by [[Alexander Shulgin]].<ref name = "CitePiHKAL">{{CitePiHKAL|name-list-style = vanc }}</ref> In his book ''[[PiHKAL]]'' (''Phenethylamines i Have Known And Loved''), Shulgin listed the dosage range as 100–160 mg, and the duration as approximately 3–6 hours.<ref name = "CitePiHKAL" /> He describes MDOH as being very psychedelic and producing increased pleasure in beauty and nature.<ref name = "CitePiHKAL" /> He also mentioned several negative side effects also seen with [[MDMA]] ("Ecstasy") such as difficulty urinating and internal dryness.<ref name = "CitePiHKAL" /> |
||
== References == |
== References == |
||
Line 34: | Line 49: | ||
* [http://pihkal.info/read.php?domain=pk&id=114 MDOH entry in PiHKAL • info] |
* [http://pihkal.info/read.php?domain=pk&id=114 MDOH entry in PiHKAL • info] |
||
⚫ | |||
⚫ | |||
{{Hallucinogens}} |
{{Hallucinogens}} |
||
{{Stimulants}} |
{{Stimulants}} |
||
{{Monoamine releasing agents}} |
|||
{{Adrenergics}} |
|||
{{Dopaminergics}} |
|||
{{Serotonergics}} |
|||
{{Phenethylamines}} |
{{Phenethylamines}} |
||
{{MDxx}} |
|||
{{DEFAULTSORT:Methylenedioxy-N-hydroxyamphetamine, 3, 4-}} |
|||
{{pharmacology-stub}} |
|||
[[Category:Substituted amphetamines]] |
|||
⚫ | |||
[[Category:Benzodioxoles]] |
|||
[[Category:Serotonin-norepinephrine-dopamine releasing agents]] |
|||
[[Category:Entactogens and empathogens]] |
|||
[[Category:Hydroxylamines]] |
|||
[[Category:Human drug metabolites]] |
|||
[[Category:Psychedelic phenethylamines]] |
|||
⚫ | |||
{{nervous-system-drug-stub}} |
|||
[[ru:MDOH]] |
Latest revision as of 03:41, 10 May 2024
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C10H13NO3 |
Molar mass | 195.218 g·mol−1 |
3D model (JSmol) | |
|
3,4-Methylenedioxy-N-hydroxyamphetamine (MDOH, MDH, N-hydroxytenamphetamine) is an entactogen, psychedelic, and stimulant of the phenethylamine and amphetamine chemical classes.[1] It is the N-hydroxy homologue of MDA, and the N-desmethyl homologue of MDHMA. MDOH was first synthesized and assayed by Alexander Shulgin.[2] In his book PiHKAL (Phenethylamines i Have Known And Loved), Shulgin listed the dosage range as 100–160 mg, and the duration as approximately 3–6 hours.[2] He describes MDOH as being very psychedelic and producing increased pleasure in beauty and nature.[2] He also mentioned several negative side effects also seen with MDMA ("Ecstasy") such as difficulty urinating and internal dryness.[2]
References
[edit]- ^ de Boer D, Bosman I (April 2004). "A new trend in drugs-of-abuse; the 2C-series of phenethylamine designer drugs". Pharmacy World & Science. 26 (2): 110–113. doi:10.1023/b:phar.0000018600.03664.36. PMID 15085947.
- ^ a b c d Shulgin A, Shulgin A (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628.
External links
[edit]